IRADIMED Names John F. Glenn Chief Financial Officer
May 26 2022 - 4:05PM
IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John
(Jack) Glenn has been appointed Chief Financial Officer effective
on or before June 20, 2022. Mr. Glenn will assume responsibility
for all areas of accounting and finance, including business
planning and modeling, organizational resource planning, investor
and analyst relations, and required reporting and related filings
with the SEC.
Mr. Glenn, 60, is a Financial Executive with over 30 years’
experience directing corporate finance activities of public and
private companies with an established record in significantly
growing enterprise value. Mr. Glenn comes to IRADIMED from
Esko Bionics Holdings, Inc., a developer of exoskeleton solutions
that amplify human potential by supporting or enhancing strength,
endurance, and mobility across medical and industrial applications.
Prior to serving as Chief Financial Officer at Esko Bionics, Mr.
Glenn served as Chief Financial Officer for Sonendo, Inc., a
privately-held, venture-backed company. His prior experience also
includes serving as Chief Financial Officer, at several other
companies, including Armetheon Corporation, a privately-held
biopharmaceutical company; Solta Medical, where he assisted in the
company’s strategic acquisition by Valeant Pharmaceutical;
Cholestech, which was acquired by Alere Medical; and Invivo
Corporation, which was sold to Intermagnetics General Corporation.
Mr. Glenn received his MBA in Finance from Santa Clara University
and his B.S. in Business Administration from the University of
Nevada.
“Jack is a seasoned financial executive with a strong background
in the medical device industry and we are excited to have him join
us as Chief Financial Officer. His strategic financial management
mindset will support IRADIMED’s continued strong growth
trajectory,” said Roger Susi, President and Chief Executive Officer
of the Company.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in the development of MRI
compatible medical devices. We are the only known provider of
non-magnetic intravenous (IV) infusion pump systems that are
specifically designed to be safe for use during magnetic resonance
imaging (MRI) procedures. We were the first to develop an infusion
delivery system that largely eliminates many of the dangers and
problems present during MRI procedures. Standard infusion pumps
contain magnetic and electronic components which can create radio
frequency (RF) interference and are dangerous to operate in the
presence of the powerful magnet that drives an MRI system. Our
patented MRidium® MRI compatible IV infusion pump system has been
designed with a non-magnetic ultrasonic motor, uniquely-designed
non-ferrous parts and other special features in order to safely and
predictably deliver anesthesia and other IV fluids during various
MRI procedures. Our pump solution provides a seamless approach that
enables accurate, safe and dependable fluid delivery before, during
and after an MRI scan, which is important to critically-ill
patients who cannot be removed from their vital medications, and
children and infants who must generally be sedated in order to
remain immobile during an MRI scan.
Our 3880 MRI compatible patient vital signs monitoring system
has been designed with non-magnetic components and other special
features in order to safely and accurately monitor a patient’s
vital signs during various MRI procedures.
The IRADIMED 3880 system operates dependably in magnetic
fields up to 30,000 gauss, which means it can operate virtually
anywhere in the MRI scanner room, including in very close proximity
to the MRI scanner bore. The IRADIMED 3880 has a compact,
lightweight design allowing it to travel with the patient from
their critical care unit, to the MRI and back, resulting in
increased patient safety through uninterrupted vital signs
monitoring and decreasing the amount of time critically ill
patients are away from critical care units. The features of
the IRADIMED 3880 include: wireless ECG with dynamic gradient
filtering; wireless SpO2 using Masimo® algorithms; non-magnetic
respiratory CO2; non-invasive blood pressure; patient temperature,
and; optional advanced multi-gas anesthetic agent unit featuring
continuous Minimum Alveolar Concentration measurements.
The IRADIMED 3880 MRI compatible patient vital signs
monitoring system has an easy-to-use design and allows for the
effective communication of patient vital signs information to
clinicians. Our 3880 MRI compatible patient vital signs monitoring
system is currently available to international customers. Once we
receive FDA 510(k) clearance, the 3880 will be available to U.S.
customers. We currently anticipate commencing marketing the 3880 to
U.S. customers in the third quarter of 2017.
For more information please visit www.iradimed.com.
Media Contact:Matt GarnerController – Interim CFOIRADIMED
CORPORATION(407) 677-8022 InvestorRelations@iradimed.com
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From May 2024 to Jun 2024
iRadimed (NASDAQ:IRMD)
Historical Stock Chart
From Jun 2023 to Jun 2024